The stock of 3D Signatures Inc (CVE:DXD) gapped down by $0.01 today and has $0.54 target or 12.00% below today’s $0.61 share price. The 9 months technical chart setup indicates high risk for the $27.42M company. The gap down was reported on Nov, 4 by Barchart.com. If the $0.54 price target is reached, the company will be worth $3.29M less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. About 76,995 shares traded hands or 19.76% up from the average. 3D Signatures Inc (CVE:DXD) has risen 6.00% since October 5, 2016 and is uptrending. It has outperformed by 4.91% the S&P500.
More notable recent 3D Signatures Inc (CVE:DXD) news were published by: Marketwired.com which released: “3D Signatures Inc. Announces Closing of Qualifying Transaction” on September 09, 2016, also Marketwired.com with their article: “3D Signatures Inc. Appoints Jason Flowerday as New CEO” published on September 27, 2016, Marketwired.com published: “3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and …” on May 26, 2016. More interesting news about 3D Signatures Inc (CVE:DXD) were released by: Marketwired.com and their article: “3D Signatures Inc. Commences Trading September 13th Under the Symbol (TSX …” published on September 12, 2016 as well as Marketwired.com‘s news article titled: “3D Signatures Inc. and Plicit Capital Corp. Execute Definitive Licencing and …” with publication date: July 21, 2016.
3D Signatures Inc, formerly Plicit Capital Corp, is a Canada personalized medicine firm with a software platform based on the three-dimensional analysis of telomere organization. The company has a market cap of $27.42 million. The Company’s software technology and prognostic methodology targets various diseases that demonstrate genomic instability, including cancer and neurological disorders. It currently has negative earnings. It is engaged in developing over five diagnostic and prognostic products for cancers and neurological disorders, including 3D Telo-PC, 3D Telo-RS, 3D Telo-MM, 3D Telo-BC, 3D Telo-LC and 3D Telo-AD.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.